Exide Technologies (NASDAQ:XIDE) down by 42.58%, BSD Medical Corporation (NASDAQ:BSDM)

Posted by Ryan Mandell May 28, 2013 0 Comment 1938 views


Hartford, CT 05/28/2013 (GDPInsider) – In Friday’s trading session, Exide Technologies (NASDAQ:XIDE) dipped by 42.58%. Its opening price of $0.78 rose to touch an intraday high of $0.79 which eventually headed down to close at $0.39 per share. More than 27.14 million shares exchanged hands in the last trading session. This number stood above the average volume of 3.38 million that was measured over a 30-day period.

Shares of Exide Technologies (NASDAQ:XIDE) collapsed to a nine-year low. This took place post a report that it had hired Lazard and Akin Gump Strauss Hauer & Feld to provide it with advice about restructuring and the possibility of a Chapter 11 filing. Last year, the company had engaged Deutsche Bank to lead a global re-financing. However, that particular effort had failed. The company’s management is now considering some restructuring alternatives that are more aggressive. This is taking place amidst an impending September maturity on the company’s convertible notes.

Is XIDE a solid investment at these levels? Get valuable updates and exclusive insights here.

In Friday’s trading session, BSD Medical Corporation (NASDAQ:BSDM) dipped by 7.46%. Its opening price of $1.31 rose to touch an intraday high of $1.38 which eventually headed down to close at $1.20 per share. More than 0.545 million shares exchanged hands in the last trading session. This number stood above the average volume of 0.264 million that was measured over a 30-day period.

The 52-week low price of the BSD Medical Corp. (NASDAQ:BSDM) shares is $0.76 per share while the 52-week high price of the shares is $2.41 per share. BSDM is involved in developing and distributing medical systems that use heat in the treatment of cancer patients. The medical systems that are developed by BSDM utilize focused radio frequency as well as microwave energy for cancer treatment. BSD Medical Corp. (NASDAQ:BSDM) is focused on producing and commercializing products for cancer treatment and has expansion plans for other medical ailments and diseases.

How Should Investors Trade BSDM Now? Get key and important information right here.

Disclosure:

WallStreetAnalyzed.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetAnalyzed.com website, for complete risks and disclosures.


About Ryan Mandell

Ryan Mandell is our senior staff writer covering the White House for Political Report, Ryan also coordinates with the main newsroom news items and contributing write-ups on cultural, social and political activities. Ryan holds an undergraduate degree in journalism, a Doctorate in international relations and a Master Degree in mass communications with an emphasis in print journalism. Ryan also covered the International Society of Social Defense congress in Spain in 2007 and taken part in the Global Forum on economic policies

View all post by Ryan Mandell Visit author's website

Write Your Comment